Research programme: eye disorder therapeutics - GrayBug

Drug Profile

Research programme: eye disorder therapeutics - GrayBug

Alternative Names: GB-201- GrayBug Vision; GB-202; GB-203

Latest Information Update: 16 May 2017

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator GrayBug inc.
  • Class Eye disorder therapies; Small molecules
  • Mechanism of Action Platelet-derived growth factor inhibitors; Protein tyrosine kinase inhibitors; Vascular endothelial growth factors inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Glaucoma; Wet age-related macular degeneration

Most Recent Events

  • 10 May 2017 Early research in Glaucoma in USA (Subconjunctival) (Graybug pipeline, May 2017)
  • 10 May 2017 Preclinical trials in Keratoplasty rejection (Corneal graft rejection) in USA (unspecified route) (Graybug pipeline, May 2017)
  • 10 May 2017 Preclinical trials in Wet age-related macular degeneration in USA (Intravitreous) (Graybug pipeline, May 2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top